• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
  • approach
  • pipeline
  • news & insights
    • presentations
    • press releases
    • references (PRL-02)
    • references (CGS-200-5)
  • careers
  • contact
  • Menu Menu
  • newsworthy &
    insightful

    Stay updated and informed about all things Propella.

Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-08 20:19:312021-09-09 15:22:13Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 george https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg george2021-01-08 19:56:432021-09-09 15:22:19Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies

Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 neil https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg neil2020-06-02 11:11:022021-09-09 15:22:24Press Release: Leading Drug Innovator Reorganizes into Two Separate Companies

Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee

The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 altusdevsite_4grsdf https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg altusdevsite_4grsdf2020-01-23 20:58:432021-09-09 15:22:29Press Release: New Osteoarthritis (OA) Treatment Guidelines Issued … Expert Medical Organization Conditionally Recommends the Use of Topical Capsaicin for Pain due to OA of the Knee

Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain

News coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 neil https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg neil2019-12-18 17:49:002021-09-09 15:32:26Well-Tolerated Topical Capsaicin Formulation Reduces Knee OA Pain

Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)

Propella Therapeutics, Inc. presented “A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)” at the Annual Meeting of the American College of Rheumatology in Atlanta, GA on November 12, 2019.

Read more
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg 0 0 neil https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg neil2019-11-12 19:45:002022-09-12 13:09:17Presentation at the Annual Meeting of the American College of Rheumatology (November 12, 2019; Atlanta, GA): A phase 2 double-blind clinical trial to examine the comparative effects on osteoarthritic knee pain of CGS-200- 1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Page 6 of 7«‹4567›

categories

  • presentations
  • press releases
  • references (CGS-200-5)
  • references (PRL-02)
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • careers
  • contact
© 2020-2023 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top